Dyadic Expands IP Protection and Business Development Activities in Japan

About this update from Dyadic International, Inc.

Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. The Japan Patent Office allowed claims covering novel aspects of Dyadic's proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone adds significant protection to the Company's expanding global intellectual property portfolio and reinforces the strength of Dyadic's differentiated C1 and Dapibus™ microbial production platforms. "This patent represents an important milestone in our strategy to expand Dyadic's intellectual property position and commercial opportunities in one of the world's most advanced biotechnology markets," said Joe Hazelton, Dyadic's President and Chief Operating Officer. As part of its international growth strategy, Dyadic engaged Intralink, a leading international business development and market expansion firm, to support expansion efforts in Japan and other key markets. These efforts have generated targeted engagement opportunities with prospective partners, customers, and collaborators across the biotechnology, pharmaceutical, food, nutrition, life sciences, cosmetics, and industrial sectors. Mr. Hazelton is scheduled to meet with several high-potential existing and prospective partners during a business development visit in early July. Japan is a strategic market for Dyadic, recognized for its leadership in regenerative medicine, biologics manufacturing, precision fermentation, advanced bioprocessing, biopharmaceuticals, cosmetics, food and nutrition technologies, and life sciences innovation. The Company believes its enhanced intellectual property protection, Intralink's local business development support, and planned in-country engagements position Dyadic to capitalize on growing demand for scalable recombinant protein solutions. "As we continue tra...

View stock analysis, news, and events for Dyadic International, Inc.